Lidds AB Asset Resilience Ratio
Lidds AB asset resilience ratio. Lidds AB (LIDDS) has an Asset Resilience Ratio of 87.39% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Lidds AB fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lidds AB (2016–2024)
Asset resilience ratio of Lidds AB from 2016 to 2024. This chart shows how Lidds AB's Asset Resilience Ratio has changed over time. Read Lidds AB debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lidds AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lidds AB (LIDDS) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr1.73 Million | 87.39% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr1.73 Million | 87.39% |
Asset Resilience Insights
- Very High Liquidity: Lidds AB maintains exceptional liquid asset reserves at 87.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Lidds AB Industry Peers by Asset Resilience Ratio
Compare Lidds AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
Lidds AB Asset Resilience Ratio by Year (2016–2024)
Lidds AB asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Lidds AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 67.49% | Skr5.51 Million ≈ $592.53K |
Skr8.16 Million ≈ $877.93K |
-9.04pp |
| 2023-12-31 | 76.53% | Skr13.51 Million ≈ $1.45 Million |
Skr17.66 Million ≈ $1.90 Million |
+56.25pp |
| 2022-12-31 | 20.29% | Skr5.26 Million ≈ $565.84K |
Skr25.92 Million ≈ $2.79 Million |
-40.89pp |
| 2021-12-31 | 61.18% | Skr34.00 Million ≈ $3.66 Million |
Skr55.58 Million ≈ $5.98 Million |
-5.37pp |
| 2020-12-31 | 66.55% | Skr36.07 Million ≈ $3.88 Million |
Skr54.20 Million ≈ $5.83 Million |
+61.77pp |
| 2019-12-31 | 4.78% | Skr7.56 Million ≈ $813.76K |
Skr158.09 Million ≈ $17.01 Million |
-11.22pp |
| 2018-12-31 | 16.00% | Skr26.14 Million ≈ $2.81 Million |
Skr163.38 Million ≈ $17.58 Million |
+4.31pp |
| 2017-12-31 | 11.69% | Skr15.29 Million ≈ $1.65 Million |
Skr130.81 Million ≈ $14.08 Million |
-3.75pp |
| 2016-12-31 | 15.44% | Skr18.68 Million ≈ $2.01 Million |
Skr121.01 Million ≈ $13.02 Million |
-- |
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more